What does ENDOCEUTICS do?

ENDOCEUTICS is a wholesaler in Brussel. Public Limited, started on 6 December 2018.

What is the address of ENDOCEUTICS?

The registered office of ENDOCEUTICS is located at Belliardstraat 40, 1040 Brussel.

Is ENDOCEUTICS still active?

Yes. According to the CBE (31 October 2026) ENDOCEUTICS is active, legal situation “Normale toestand”, started on 6 December 2018.

Is ENDOCEUTICS registered on Peppol?

Yes, ENDOCEUTICS is registered on the Peppol network with ID 0208:0715565040.

What is the enterprise number of ENDOCEUTICS?

The enterprise number of ENDOCEUTICS is BE0715565040.

When was ENDOCEUTICS founded?

ENDOCEUTICS was founded on 6 December 2018.

Who are the directors of ENDOCEUTICS?

According to the 2025 annual accounts, the directors of ENDOCEUTICS are: MYRIEL PHARMACEUTICALS ULC, MYRIEL PHARMACEUTICAL LLC.

Is ENDOCEUTICS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 December 2018; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did ENDOCEUTICS make in 2025?

ENDOCEUTICS posted a profit after taxes of € 348,842 in financial year 2025.

What is the revenue of ENDOCEUTICS?

As a small company, ENDOCEUTICS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 415,353.

ENDOCEUTICS (Public Limited) - Brussel - BE0715565040

Dossier ENDOCEUTICS, printed on 31 October 2026 from databakkes.be/en/0715565040/endoceutics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

97 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

ENDOCEUTICS from Brussel, company number BE0715565040, closed financial year 2025 with a result of € 348,842 after tax. For that financial year ENDOCEUTICS recorded a gross margin of € 415,353 and equity of € 234,743. Compared with financial year 2024, the result moved from € 119,480 to € 348,842. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2026.

What it is worth Growing

€ 234,743

▲ € 348,842 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 348,842

▲ 192% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 611,138

▲ 45% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 173,243.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1.3 million

▼ 59% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 63,065

▼ 9% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 148,685 Gross margin 2022: € 148,685 First fiscal year in the series	€ 12,840 Gross margin 2023: € 12,840 ▼ 91% vs 2022 (€ 148,685) Unfavourable step	€ 123,176 Gross margin 2024: € 123,176 ▲ € 110,336 vs 2023 (€ 12,840) Favourable step	€ 415,353 Gross margin 2025: € 415,353 ▲ 237% vs 2024 (€ 123,176) Favourable step	▲ 237%
Profit after taxes	€ 148,005 Profit after taxes 2022: € 148,005 First fiscal year in the series	€ 9,374 Profit after taxes 2023: € 9,374 ▼ 94% vs 2022 (€ 148,005) Unfavourable step	€ 119,480 Profit after taxes 2024: € 119,480 ▲ € 110,107 vs 2023 (€ 9,374) Favourable step	€ 348,842 Profit after taxes 2025: € 348,842 ▲ 192% vs 2024 (€ 119,480) Favourable step	▲ 192%
Equity	€ -242,953 Equity 2022: € -242,953 First fiscal year in the series	€ -233,580 Equity 2023: € -233,580 ▲ € 9,374 vs 2022 (€ -242,953) Favourable step	€ -114,099 Equity 2024: € -114,099 ▲ € 119,480 vs 2023 (€ -233,580) Favourable step	€ 234,743 Equity 2025: € 234,743 ▲ € 348,842 vs 2024 (€ -114,099) Favourable step	▲ € 348,842
Total debts	€ 884,335 Total debts 2022: € 884,335 First fiscal year in the series	€ 1,272,172 Total debts 2023: € 1,272,172 ▲ 44% vs 2022 (€ 884,335) Unfavourable step	€ 4,819,774 Total debts 2024: € 4,819,774 ▲ 279% vs 2023 (€ 1,272,172) Unfavourable step	€ 3,218,701 Total debts 2025: € 3,218,701 ▼ 33% vs 2024 (€ 4,819,774) Favourable step	▼ 33%
Cash	€ 256,457 Cash 2022: € 256,457 First fiscal year in the series	€ 51,740 Cash 2023: € 51,740 ▼ 80% vs 2022 (€ 256,457) Unfavourable step	€ 421,485 Cash 2024: € 421,485 ▲ € 369,745 vs 2023 (€ 51,740) Favourable step	€ 611,138 Cash 2025: € 611,138 ▲ 45% vs 2024 (€ 421,485) Favourable step	▲ 45%
Retained profit	€ -304,453 Retained profit 2022: € -304,453 First fiscal year in the series	€ -295,080 Retained profit 2023: € -295,080 ▲ € 9,374 vs 2022 (€ -304,453) Favourable step	€ -175,599 Retained profit 2024: € -175,599 ▲ € 119,480 vs 2023 (€ -295,080) Favourable step	€ 173,243 Retained profit 2025: € 173,243 ▲ € 348,842 vs 2024 (€ -175,599) Favourable step	▲ € 348,842
Balance sheet total	€ 641,382 Balance sheet total 2022: € 641,382 First fiscal year in the series	€ 1,038,593 Balance sheet total 2023: € 1,038,593 ▲ 62% vs 2022 (€ 641,382) Unchanged	€ 4,705,675 Balance sheet total 2024: € 4,705,675 ▲ € 3.7 million vs 2023 (€ 1,038,593) Unchanged	€ 3,453,444 Balance sheet total 2025: € 3,453,444 ▼ 27% vs 2024 (€ 4,705,675) Unchanged	▼ 27%

Key figures of ENDOCEUTICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ENDOCEUTICS?

What happened at ENDOCEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 29, 2026 New annual accounts for financial year 2025: profit of € 348,842 (▲ 192% vs 2024). filed late Source: NBB ↗
2023 MYRIEL PHARMACEUTICALS ULC became a director. NBB
2023 MYRIEL PHARMACEUTICAL LLC became a director. NBB
Dec 6, 2018 Start of the company according to the CBE. KBO

In short

From € 148,005 profit in 2022 to € 348,842 profit in 2025.

Paid € 63,065 in corporate taxes since 2022.

Best year ever: 2025, with € 348,842 profit.

Original PDFs at the National Bank ↗

Management

MYRIEL PHARMACEUTICAL LLC 100%

MYRIEL PHARMACEUTICALS ULC 0%

ENDOCEUTICS

Behind ENDOCEUTICS are MYRIEL PHARMACEUTICALS ULC and MYRIEL PHARMACEUTICAL LLC. The shares are held by MYRIEL PHARMACEUTICAL LLC (100%) and MYRIEL PHARMACEUTICALS ULC (0%).

Directors

According to the 2025 annual accounts

MYRIEL PHARMACEUTICALS ULC

Director · represented by APURVA OM SARAF

since 2023

MYRIEL PHARMACEUTICAL LLC

Director · represented by John Maher

since 2023

Shareholders

MYRIEL PHARMACEUTICAL LLC

100%

MYRIEL PHARMACEUTICALS ULC

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Belliardstraat 40

1040 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 97 companies are registered at this address.

All companies at this address →

ASSOCIATION EUROPEENNE DU CHARBON ET DU LIGNITE

The European Petrochemical Association

€ 2.7 million gross margin · 2025

CONSEIL EUROPEEN DE L'INDUSTRIE CHIMIQUE - EUROPEAN CHEMICAL INDUSTRY COUNCIL

€ 4.4 million revenue · 2025

CBRE Investment Management Belgium

€ 4.2 million revenue · 2025

Plastics Europe

+92 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0715.565.040
VAT number: BE 0715.565.040
Registered office: Belliardstraat 40, 1040 Brussel
Names & denominations: ENDOCEUTICS
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 6 December 2018
Peppol: Active · Active since 16 Dec 2025
Activities · NACE: Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗